Trial name | Other adverse outcomes | Follow up period | DAPT use |
---|---|---|---|
DUTCH PEERS [17] | TVF, all-cause death, cardiac death, TVMI, any TVR, clinically indicated TVR, clinically indicated TLR, TLF, MACEs, patient-oriented composite endpoint | 12 months | 1 year |
HOST-ASSURE [18] | TLF, all-cause death, cardiac death, TVMI, repeated revascularization, TLR, TVR, CVA, TVF, patient-oriented composite endpoint | 12 months | 1 year |
Lin 2015 [15] | Adverse cardiac events, all-cause death, cardiac death, MI | 15 months | 1 year |
Mehilli 2013 [16] | All-cause death, MI, stroke, TLR, patient-oriented composite endpoint | 12 months | 1 year |
RESOLUTE [19] | TLR, all-cause death, cardiac death, TVMI, clinically indicated TLR, MI, clinically indicated TVR, MACEs, patient-oriented composite endpoint, TVF | 12 months | 6 months to 1 year |
TWENTE [20] | TVF, all-cause death, cardiac death, TVMI, clinically indicated TVR, TLF, clinically indicated TLR, MACEs, patient-oriented composite endpoint | 12 months | 1 year |